Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen: http://dx.doi.org/10.25673/117021
Titel: Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss : study protocol for a three-armed, randomized, triple-blind, multicenter trial (HODOKORT)
Autor(en): Plontke, Stefan K.-R.In der Gemeinsamen Normdatei der DNB nachschlagen
Girndt, MatthiasIn der Gemeinsamen Normdatei der DNB nachschlagen
Meisner, Christoph
Böselt, IrisIn der Gemeinsamen Normdatei der DNB nachschlagen
Ludwig-Kraus, Beatrice
Richter, MichaelIn der Gemeinsamen Normdatei der DNB nachschlagen
Rahne, TorstenIn der Gemeinsamen Normdatei der DNB nachschlagen
Erscheinungsdatum: 2022
Art: Artikel
Sprache: Englisch
Zusammenfassung: Background: Systemic glucocorticosteroids (“steroids”) are widely used worldwide as a standard of care for primary therapy of idiopathic sudden sensorineural hearing loss (ISSHL). The German ISSHL guideline recommends high-dose steroids without evidence from randomized controlled trials (RCTs) and refers solely to retrospective cohort studies. This RCT aims to assess the efficacy (improvement in hearing) and safety (especially systemic side effects) of high-dose steroids versus standard of care (standard dose systemic steroids) for the treatment of unilateral ISSHL, when given as a primary therapy. Methods: The study is designed as a multicenter (approximately 40 centers), randomized, triple-blind, three-armed, parallel group, clinical trial with 312 adult patients. The interventions consist of 5 days of 250 mg/day intravenous prednisolone (intervention 1) + oral placebo, or 5 days of 40 mg/day oral dexamethasone (intervention 2) + intravenous placebo. The control intervention consists of 60 mg oral prednisolone for 5 days followed by five tapering doses + intravenous placebo. The primary efficacy endpoint is the change in hearing threshold in the three most affected contiguous frequencies between 0.25 and 8 kHz 1 month after ISSHL. Secondary endpoints include further measures of hearing improvement including speech audiometry, tinnitus, quality of life, blood pressure, and altered glucose tolerance. Discussion: There is an unmet medical need for an effective medical therapy of ISSHL. Although sensorineural hearing impairment can be partially compensated by hearing aids or cochlear implants (CI), generic hearing is better than using hearing aids or CIs. Since adverse effects of a short course of high-dose systemic corticosteroids have not been documented with good evidence, the trial will improve knowledge on possible side effects in the different treatment arms with a focus on hyperglycemia and hypertension.
URI: https://opendata.uni-halle.de//handle/1981185920/118981
http://dx.doi.org/10.25673/117021
Open-Access: Open-Access-Publikation
Nutzungslizenz: (CC BY 4.0) Creative Commons Namensnennung 4.0 International(CC BY 4.0) Creative Commons Namensnennung 4.0 International
Journal Titel: HNO
Verlag: Springer
Verlagsort: Berlin
Band: 70
Heft: Suppl 2
Originalveröffentlichung: 10.1007/s00106-022-01184-8
Seitenanfang: 30
Seitenende: 44
Enthalten in den Sammlungen:Open Access Publikationen der MLU

Dateien zu dieser Ressource:
Datei Beschreibung GrößeFormat 
s00106-022-01184-8.pdf429.15 kBAdobe PDFMiniaturbild
Öffnen/Anzeigen